Functional Genetics, Inc.
About Functional Genetics
Functional Genetics, Inc. (FGI) is a development-stage biotechnology company that uses innovative science to develop new therapeutics for infectious disease. Our novel antiviral products address widespread and intractable diseases that have persistently inflicted considerable suffering and death.
Our products facilitate simultaneous targeting of multiple co-morbid pathogens with a single drug. Examples include targeting of distinct respiratory viruses (RSV, PIV, influenza), hepatitis viruses (HBV, HCV), sexually-transmitted diseases (HIV, Herpes) or biothreat (Ebola, Marburg) agents.
Our new antiviral drugs (small molecule and monoclonal antibodies) are crafted to be broad-spectrum in application and durable in response. Based on our approach, we minimize the potential for the outgrowth of drug-resistant viruses.
Our first IND is scheduled for 2009 with two additional INDs for different products to be filed in 2010.
The Company was originally formed to advance a novel technology to discover novel targets and pathways. This RHGP technology can interrogate the entire genome to identify causative events for new target discovery. FGI and its collaborators have successfully utilized RHGP to identify novel targets for oncology, infectious disease, cardiovascular disease, Alzheimer's disease and enhanced production of biologics-based therapeutics.
- Industry : Pharma
Here you will find Functional Genetics, Inc.
Last viewed contents
UGR Scientists design Molecules with a higher selective ability to exterminate cancer cells
GeneProt and Lundbeck Collaborate in CNS Proteomics
Enigma Diagnostics Expands Its US and European Executive Management Teams
Clavis Pharma recruits first patient in pivotal Phase III study of elacytarabine in late-stage acute myeloid leukaemia - Clinical trial aims to confirm significant survival benefit seen in Phase II
Researchers Create New Organic Gel Nanomaterials
Wirtschaftsgenossenschaft deutscher Tierärzte eG - Garbsen, Germany
Heart_block
Reserpine
Supergen and Astex Therapeutics enter definitive merger agreement
